Assessing Methylation of Mir-146b in Patients with Non-Small Cell Lung Cancer

Masoumeh Masrouri, Elham sadat Hosseini manesh, Mahsa Sadeghiazad, Morteza Karimipoor, Shohreh Zare Karizi


Background: One of the most important epigenetic factors in lung cancer is aberrant DNA methylation. So far, many studies have been performed on the methylation of various genes and microRNAs in various cancers, especially lung cancer. So because of the high importance of microRNAs in cancer. In this study, mir-146b methylation was checked in NSCLC tissues.

Method: Analysis methylation of mir146b was investigated in 30 samples NSCLC tissues and 30 adjacent normal tissues using by MS-HRM method.

Results: Study on mir146b methylation showed that there was no significant difference between the methylation levels of this microRNA in tumor samples compared with healthy samples (P>0.05). However, this study was designed as a pilot study, and further investigations are required to confirm our findings.


Lung Cancer; NSCLC; Mir-146b; MS-HRM Method.

Full Text:



Tang N, Guo J, Zhang Q, Wang Y, Wang Z. Greater efficacy of chemotherapy plus bevacizumab compared to chemo-and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget. 2016;7(3):3635.

Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology and Prevention Biomarkers. 2010;19(8):1893-907.

Risch A, Plass C. Lung cancer epigenetics and genetics. International journal of cancer. 2008;123(1):1-7.

Tanaka K, Kumano K, Ueno H. Intracellular signals of lung cancer cells as possible therapeutic targets. Cancer science. 2015;106(5):489-96.

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-500.

Cruz CSD, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clinics in chest medicine. 2011;32(4):605-44.

Council NR. Health effects of exposure to radon: BEIR VI: National Academies Press; 1999.

Turner MC, Krewski D, Pope III CA, Chen Y, Gapstur SM, Thun MJ. Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers. American journal of respiratory and critical care medicine. 2011;184(12):1374-81.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016;66(1):7-30.

Yu XQ, Luo Q, Kahn C, Grogan P, O’Connell DL, Jemal A. Contrasting temporal trends in lung cancer incidence by socioeconomic status among women in New South Wales, Australia, 1985–2009. Lung Cancer. 2017;108:55-61.

Langevin SM, Kratzke RA, Kelsey KT. Epigenetics of lung cancer. Translational Research. 2015;165(1):74-90.

Lee Y-C, Wang H-P, Wang C-P, Ko J-Y, Lee J-M, Chiu H-M, et al. Revisit of field cancerization in squamous cell carcinoma of upper aerodigestive tract: better risk assessment with epigenetic markers. Cancer prevention research. 2011:canprevres. 0096.2011.

Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21(35):5427.

Esteller M. Non-coding RNAs in human disease. Nature Reviews Genetics. 2011;12(12):861.

Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald SM, et al. Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer. 2014;83(2):272-8.

Kota SK, Balasubramanian S. Cancer therapy via modulation of micro RNA levels: a promising future. Drug discovery today. 2010;15(17-18):733-40.

Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clinical lung cancer. 2009;10(1):42-6.

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer cell. 2006;9(3):189-98.

Omrane I, Kourda N, Stambouli N, Privat M, Medimegh I, Arfaoui A, et al. MicroRNAs 146a and 147b biomarkers for colorectal tumor’s localization. BioMed research international. 2014;2014.

Suzuki Y, Kim HW, Ashraf M, Haider HK. Diazoxide potentiates mesenchymal stem cell survival via NF-κB-dependent miR-146a expression by targeting Fas. American Journal of Physiology-Heart and Circulatory Physiology. 2010;299(4):H1077-H82.

Chou C-K, Chen R-F, Chou F-F, Chang H-W, Chen Y-J, Lee Y-F, et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAFV600E mutation. Thyroid. 2010;20(5):489-94.

Hsu S-D, Chu C-H, Tsou A-P, Chen S-J, Chen H-C, Hsu PW-C, et al. miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic acids research. 2007;36(suppl_1):D165-D9.

Belinsky SA. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis. 2005;26(9):1481-7.

Li Y, Zhang H, Dong Y, Fan Y, Li Y, Zhao C. MiR-146b-5p functions as a suppressor miRNA and prognosis predictor in non-small cell lung cancer. Journal of Cancer. 2017;8(9):1704.

Ding H-Y, Qian W-Q, Xu J. MicroRNA-146b acts as a potential tumor suppressor in human prostate cancer. Journal of BU ON: official journal of the Balkan Union of Oncology. 2016;21(2):434-43.

He Y, Yu Y-C, Zhu H-C, Jing X-J, Wei N, Wang P-D, et al. MicroRNA-146 inhibits epithelial-mesenchymal transition by regulating FOXM1 in lung cancer cells. Int J Clin Exp Pathol. 2017;10(3):3085-92.


  • There are currently no refbacks.

Copyright (c) 2018 Arash Matin ahmadi

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.